4,238 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by PFW Advisors LLC

PFW Advisors LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 4,238 shares of the medical research company’s stock, valued at approximately $1,105,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Miracle Mile Advisors LLC grew its stake in shares of Amgen by 3.0% during the 4th quarter. Miracle Mile Advisors LLC now owns 6,016 shares of the medical research company’s stock worth $1,568,000 after purchasing an additional 176 shares during the period. Horizon Wealth Management LLC increased its holdings in Amgen by 13.3% in the fourth quarter. Horizon Wealth Management LLC now owns 1,217 shares of the medical research company’s stock valued at $317,000 after buying an additional 143 shares in the last quarter. Burns J W & Co. Inc. NY raised its position in shares of Amgen by 0.5% in the fourth quarter. Burns J W & Co. Inc. NY now owns 22,349 shares of the medical research company’s stock worth $5,825,000 after acquiring an additional 117 shares during the period. Elevated Capital Advisors LLC raised its position in shares of Amgen by 8.1% in the fourth quarter. Elevated Capital Advisors LLC now owns 1,664 shares of the medical research company’s stock worth $434,000 after acquiring an additional 125 shares during the period. Finally, Kwmg LLC grew its position in shares of Amgen by 3.5% during the 4th quarter. Kwmg LLC now owns 19,475 shares of the medical research company’s stock valued at $5,076,000 after acquiring an additional 651 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 3.0 %

Shares of NASDAQ AMGN traded up $7.96 during midday trading on Monday, reaching $270.19. 3,364,979 shares of the stock were exchanged, compared to its average volume of 3,085,018. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market capitalization of $145.24 billion, a P/E ratio of 34.60, a PEG ratio of 2.91 and a beta of 0.56. The company has a 50 day simple moving average of $279.10 and a 200 day simple moving average of $308.66. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the prior year, the company posted $4.96 EPS. The company’s quarterly revenue was up 23.2% on a year-over-year basis. As a group, equities analysts expect that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.52%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is 121.90%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AMGN. Deutsche Bank Aktiengesellschaft reduced their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. UBS Group decreased their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Wolfe Research began coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Bank of America reaffirmed an “underperform” rating and set a $256.00 price objective on shares of Amgen in a report on Tuesday, December 10th. Finally, Redburn Partners reduced their price target on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Amgen has a consensus rating of “Hold” and an average price target of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.